Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus
about
Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremiaSynergy between vancomycin and nafcillin against Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic modelEvolving Rapid Methicillin-resistant Staphylococcus aureus Detection: Cover All the Bases.Epidemiology and outcomes of community-onset methicillin-susceptible Staphylococcus aureus bacteraemia in a university hospital in Singapore.Epidemiology of community-onset Staphylococcus aureus infections in pediatric patients: an experience at a Children's Hospital in central Illinois.New perspectives of infections in cardiovascular diseaseCephalosporin-Glycopeptide Combinations for Use against Clinical Methicillin-Resistant Staphylococcus aureus Isolates: Enhanced In vitro Antibacterial Activity.Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.Clinical management of Staphylococcus aureus bacteremia: a review.Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.Predictors of mortality in Staphylococcus aureus BacteremiaTreatment outcomes with cefazolin versus oxacillin for deep-seated methicillin-susceptible Staphylococcus aureus bloodstream infections.Comparison of outcomes in patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia who are treated with β-lactam vs vancomycin empiric therapy: a retrospective cohort studyHealthcare-associated Staphylococcus aureus Bacteremia in Children: Evidence for Reverse Vancomycin Creep and Impact of Vancomycin Trough Values on OutcomeCAMERA2 - combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: study protocol for a randomised controlled trial.Comparative effectiveness of β-lactam versus vancomycin empiric therapy in patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia.Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia.Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? - Comparison of pharmacology and clinical efficacy.Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia.Prevention and management of central line-associated bloodstream infections in hospital practice.Metastatic complications of bloodstream infections in hemodialysis patients.The empirical combination of vancomycin and a β-lactam for Staphylococcal bacteremia.Bad bacteria in acute appendicitis: rare but relevant.Adverse Events Lead to Drug Discontinuation More Commonly among Patients Who Receive Nafcillin than among Those Who Receive Oxacillin.Current features of infective endocarditis in persons on hemodialysis: a prevalence study with case control design from the prospective multicenter SEI cohort.Ventilator-associated pneumonia by methicillin-susceptible Staphylococcus aureus: do minimum inhibitory concentrations to vancomycin and daptomycin matter?Empirical combination of a β-lactam to vancomycin may not improve outcomes of methicillin-susceptible Staphylococcus aureus bacteremia, compared to vancomycin monotherapy.Evaluation of MRSASelect (™) chromogenic medium for the early detection of methicillin-resistant Staphylococcus aureus from blood cultures.Lack of bactericidal antagonism or synergism in vitro between oxacillin and vancomycin against methicillin-susceptible strains of Staphylococcus aureus.Clinical rationale for treatment of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin.Impact of rapid methicillin-resistant Staphylococcus aureus polymerase chain reaction testing on mortality and cost effectiveness in hospitalized patients with bacteraemia: a decision model.Coagulase-negative Staphylococcus bacteraemia accounts for one third of Staphylococcus bacteraemia in a French university hospital.Redeploying β-Lactams Against Staphylococcus aureus: Repurposing With a Purpose.Effectiveness of Vancomycin or Beta-Lactam Therapy in Ampicillin-Susceptible Enterococcus spp. Bloodstream Infections.Impact of rapid diagnosis of Staphylococcus aureus bacteremia from positive blood cultures on patient management.Is empiric daptomycin effective in reducing mortality in Staphylococcus aureus bacteraemia? A real-life experience.Combination of Vancomycin and β-Lactam Therapy for Methicillin-ResistantStaphylococcus aureusBacteremia: A Pilot Multicenter Randomized Controlled TrialAntibiotic Choice May Not Explain Poorer Outcomes in Patients With Staphylococcus aureus Bacteremia and High Vancomycin Minimum Inhibitory Concentrations
P2860
Q21261829-15AA2847-1F1A-49E8-A89F-F7BFD7C885EDQ28481497-F0E518C5-A26C-497E-BDB2-50F55FBF8268Q30235503-BEDAFA5C-4FCC-44E3-83A9-8D4DFE070792Q33318589-A81C2BBD-7106-4D0D-A837-B6957D1C8065Q33483064-1B87958A-B8AF-4CF2-B0F8-7CC669825C00Q33587960-2C75BB4E-3BE3-4E14-852E-8E37E2176FC0Q33700986-C8DA7714-ED8A-485D-BB8D-B43EBBBDC3E2Q34157657-9D14B1B3-5F9E-4A69-B9FC-D4CC5DCF0E79Q34441035-E2801C1A-BA81-425F-982B-55324C715D98Q34478074-6DD31ED8-3DB4-4C1A-BC7B-7FA48EB895DFQ35940556-7ECE395F-3A72-49A3-8D00-4154FB77E351Q35960730-B799802E-6ED8-43C3-91C4-197356ACF009Q36026942-DB89446E-7EAE-46E3-8AB6-81E88CD8FF75Q36576652-3F576FE7-EA7D-40D8-ADEB-114641E31DF7Q36748977-016C050E-B3EA-4582-90AE-5E25F47D0AEDQ36836505-933C3B3F-95D9-4EC3-A8CA-5521AE87E260Q37800310-FB911A3F-47B3-4918-8346-83A17B6BEC9BQ37821604-6E951689-37D0-422E-AE13-5C05220C4D56Q37955286-B79851A2-E8DB-49E0-BA7D-0A8C7BFF87FBQ37992486-F3F616F0-652D-444E-BA49-503933B314F8Q38070697-5D0E2EE4-831B-4BF9-B727-303DF26102D1Q38132301-D87765D7-578F-4D3D-BC1C-281B24B0135AQ38677990-716184FF-59E0-4792-A761-55307E8DD657Q38895155-799B266C-DD7A-46ED-BA3F-AE4C319FBF23Q40093594-FFC9EE87-72DB-4D2B-913A-2D4141F75C91Q40264307-A6ED634F-6784-4021-8D14-084238E38FCDQ40375415-2BA9409C-2FB9-41C9-A3E6-A162ADAA882EQ41896768-7FF02789-5398-4BA5-A90F-B0148F77D1BBQ42929761-9261B4D5-195A-4012-8D49-17A0BF09D723Q42943128-52833722-5C57-4143-BA09-708B1966E632Q43021553-DCF2D24D-CD9B-40FE-B820-8FA88A958679Q45331165-4024693D-3B40-4043-BF65-C3C3975236E9Q45961041-FDCF4EC4-D5D4-41CC-BD8E-3DBAE1804CF2Q48547085-7D6C2671-F344-4EB2-929B-EFB2C51C4C06Q50498047-3ED54B63-4895-4143-902A-CD5B763B4566Q54785836-32E1677F-7D86-40E6-B619-E7B5A7116D76Q57763098-A90442C0-CF36-4FBF-B046-1A69E12E3F14Q57763234-C77D2E55-DC34-41DA-8178-1D4D55882822
P2860
Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Impact of empirical-therapy se ...... ceptible Staphylococcus aureus
@ast
Impact of empirical-therapy se ...... ceptible Staphylococcus aureus
@en
type
label
Impact of empirical-therapy se ...... ceptible Staphylococcus aureus
@ast
Impact of empirical-therapy se ...... ceptible Staphylococcus aureus
@en
prefLabel
Impact of empirical-therapy se ...... ceptible Staphylococcus aureus
@ast
Impact of empirical-therapy se ...... ceptible Staphylococcus aureus
@en
P2093
P2860
P356
P1476
Impact of empirical-therapy se ...... ceptible Staphylococcus aureus
@en
P2093
Donald P Levine
Michael J Rybak
Peggy S McKinnon
Thomas P Lodise
P2860
P304
P356
10.1128/AAC.00101-07
P407
P577
2007-07-30T00:00:00Z